CompanyMCRBNasdaqCambridge, MA

Seres Therapeutics, Inc.

Seres Therapeutics develops live biotherapeutics to treat oncology and inflammatory/immune diseases by modulating the gastrointestinal microbiome.

SEC EDGAR ClinicalTrials.gov serestherapeutics.com

6-KSep 22Latest SEC filing, period to Sep 22

Aug 5Latest story

August 2026

Seres reports SER-155 irEC trial data as it seeks partners and cuts facility costs

Aug 5Quarterly updateSeres Therapeutics, Inc.

Seres Therapeutics issues shares to former landlord to settle lease termination debt

Aug 4FinancingSeres Therapeutics, Inc.

Seres Therapeutics ends part of Cambridge lease, pays landlord in cash and stock

Aug 4PartnershipSeres Therapeutics, Inc.

July 2026

Seres Therapeutics stockholders approve incentive plan increase at reconvened annual meeting

Jul 8PeopleSeres Therapeutics, Inc.